49BA.F

BeOne Medicines AG
FrankfurtEUREQUITY Healthcare DELAYED
Last price
318.00
▲ 2.00 (0.63%)
MARKET ·

Price

1D H L Range Vol
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
306.00
Prev close
316.00
Day high
318.00
Day low
306.00
Volume
3
Market cap
$35.97B
P/E (TTM)
66.67
52W range
222.00 – 328.00

Day trading desk

Current session · delayed
Gap from prior close
-3.16%
Prior close 316.00
VWAP
318.00
0.00% from price
Relative volume
0.50×
Quiet session
Session range
3.92%
306.00 – 318.00
Position in range
100%
Near session high
ATR (14D)
12.14
3.82% of price
Prior day high
316.00
PDH
Prior day low
312.00
PDL
Bid / ask spread
Quote not published
Session volume
3
Avg 6

VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.

Trailing performance

Price return · vs SPY
Returnvs SPY
1W
+7.43% +8.8%
1M
+14.39% +10.7%
3M
+21.37% +18.3%
6M
+3.92% -7.1%
YTD
+23.26% +11.0%
1Y
+18.66% -1.3%
3Y
+60.61% -13.6%
5Y
+8.90%

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Unusual options activity

Account required
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
Free account required

Contracts trading at or above their open interest, ranked by notional and where the print landed.

Free account

5 more panels on 49BA.F open with an account.

Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.

Insider net activity

6m · Form 4 rollup
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
Net transactions
0
Buys less sells
Sell : buy shares
Not enough filings
Insider-held shares
19.64M
Total on file

Insider transactions

Account required
DateInsiderAction SharesValueHeld
Aug 12, 26
OYLER JOHN VICTOR
Chief Executive Officer
SELL 240.81K $86.48M Direct
Aug 11, 26
LEE CHAN HENRY
General Counsel
CONVERSION 2.67K $510.19K Direct
Aug 11, 26
LEE CHAN HENRY
General Counsel
SELL 2.67K $959.76K Direct
Aug 3, 26
ROSENBERG AARON
Chief Financial Officer
SELL 1.16K $361.81K Direct
Jul 30, 26
LEE CHAN HENRY
General Counsel
SELL 1.04K $337.93K Direct
Jul 22, 26
LEE CHAN HENRY
General Counsel
CONVERSION 1.67K $319.74K Direct
Jul 22, 26
LEE CHAN HENRY
General Counsel
SELL 1.67K $542.42K Direct
Jul 21, 26
OYLER JOHN VICTOR
Chief Executive Officer
SELL 109.71K $34.59M Direct
Jul 20, 26
OYLER JOHN VICTOR
Chief Executive Officer
CONVERSION 33.99K $4.08M Direct
Jul 17, 26
OYLER JOHN VICTOR
Chief Executive Officer
CONVERSION 64.63K $7.75M Direct
Jul 17, 26
OYLER JOHN VICTOR
Chief Executive Officer
SELL 64.63K $20.16M Direct
Jul 16, 26
OYLER JOHN VICTOR
Chief Executive Officer
CONVERSION 283.15K $41.14M Direct
Jul 16, 26
OYLER JOHN VICTOR
Chief Executive Officer
SELL 283.15K $89.35M Direct
Jul 14, 26
OYLER JOHN VICTOR
Chief Executive Officer
CONVERSION 133.60K $7.22M Direct
What this is, and what it is not

These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.

A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.

This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.

Free account required

Officer and director trades in their own stock, straight from Form 4 filings.

Insider holders

10 reporting
NameRelationShares heldLatest
BAKER BROS ADVISORS L.P.
Unknown Sale
BAKER BROTHERS LIFE SCIENCES, L.P.
Unknown Sale
BALL TITUS BENJAMIN
Officer 0 Sale
DUGAN MARGARET
Director 0 Sale
LEE CHAN HENRY
General Counsel 0 Conversion of Exercise of derivative security
RIVA ALESSANDRO
Director 0 Sale
ROSENBERG AARON
Chief Financial Officer 0 Sale
SANDERS CORAZON CORSEE D
Director 0 Sale
WANG LAI
Officer 0 Sale
WU XIAOBIN
President 16.36K Sale

Fundamentals

TTM · reported
Market cap$35.97B
Enterprise value$33.11B
Revenue (TTM)$6.13B
Gross profit$5.45B
EBITDA$1.07B
Net income$655.71M
EPS (TTM)$4.77
Free cash flow$879.02M
Total cash$5.10B
Total debt$2.05B
Book value / share$39.22
Shares outstanding104.27M
Float80.95M
Short % of float
Dividend yield
Beta (5Y)0.50

Valuation & profitability ratios

Account required
Trailing P/E66.67
Forward P/E-24.86
PEG ratio1.06
Price / sales
Price / book8.11
EV / revenue5.40
EV / EBITDA30.90
Gross margin88.89%
Operating margin19.06%
Profit margin10.70%
Return on equity14.66%
Return on assets7.46%
Debt / equity39.61
Current ratio3.41
Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Financial statements

As reported · 4 years · 6 quarters
Blank means not reported, not zero
Line item2025202420232022YoY
Total revenue $5.34B$3.81B$2.46B$1.42B +40.2%
Operating revenue $6.79B$4.81B$2.98B$1.59B +41.1%
Cost of revenue $668.54M$594.09M$379.92M$286.48M +12.5%
Gross profit $4.67B$3.22B$2.08B$1.13B +45.3%
Research & development $2.15B$1.95B$1.78B$1.64B +9.9%
Selling, general & admin $2.08B$1.83B$1.51B$1.28B +13.7%
Total operating expense $4.23B$3.78B$3.29B$2.92B +11.7%
Operating income $447.14M-$568.20M-$1.21B-$1.79B +178.7%
Net interest income $12.27M$47.84M$74.01M$52.48M -74.3%
Pre-tax income $416.85M-$533.00M-$825.84M-$1.96B +178.2%
Tax provision $129.92M$111.78M$55.87M$42.78M +16.2%
Net income $286.93M-$644.79M-$881.71M-$2.00B +144.5%
Net income to common $286.93M-$644.79M-$881.71M-$2.00B +144.5%
Basic EPS 2.60-6.11-8.45-19.37 +142.6%
Diluted EPS 2.47-6.12-8.45-19.37 +140.3%
EBIT $475.09M-$511.20M-$821.47M-$1.79B +192.9%
EBITDA $616.77M-$339.43M-$733.80M-$1.72B +281.7%
Basic shares 109.06M105.29M104.39M103.13M +3.6%
Diluted shares 113.45M105.29M104.39M103.13M +7.8%

Options analytics

Account required
Put / call volume
Put / call open interest
Positioning, not flow
Max pain
ATM implied vol
Nearest strike to spot
Skew (10% OTM)
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
Heaviest put OI

Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.

Free account required

Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.

Earnings

History & consensus estimates
Forward consensus
PeriodEPSAnalystsRevenueGrowth
Current quarter $1.75B +24.1%
Next quarter $1.78B +19.1%
Current year $6.75B +26.4%
Next year $7.71B +14.1%

Analyst targets & ownership

Account required
Mean target
High target
Low target
Implied upside
Analyst count
ConsensusNONE
Strong buy / Buy— / —
Hold
Sell / Strong sell— / —
Held by insiders17.28%
Held by institutions33.12%
Institutions holding389
Free account required

Price targets, consensus spread, insider and institutional ownership.

Moving averages & technicals

Computed from 2Y daily closes
SMA 10
308.20
+3.18% from price
SMA 20
294.10
+8.13% from price
SMA 50
269.80
+17.87% from price
SMA 100
261.94
+21.40% from price
SMA 200
269.49
+18.00% from price
EMA 12
304.82
+4.32% from price
EMA 26
291.99
+8.91% from price
EMA 50
279.04
+13.96% from price
RSI (14)
63.8
Neutral
MACD (12,26,9)
12.83
Hist 1.68
ATR (14)
12.14
3.82% of price
Realised vol 30D
42.7%
Annualised
Bollinger upper
327.43
20, 2σ
Bollinger lower
260.77
20, 2σ
50 / 200 cross
Golden
269.80 vs 269.49
Trend bias
Above 200
+18.00%

Options chain

Account required
ExpirySpot 318.00
Calls
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Puts
StrikeLastBidAskVolOIIV
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
000.000.000.000.00000.0%
Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Risk profile

Daily returns · 1Y window
Beta vs SPY
0.23
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
42.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-31.1%
Peak to trough
Max drawdown 5Y
-67.5%
Peak to trough
ATR 14
12.14
3.82% of price
Beta (reported)
0.50
5Y monthly, from filing

Rating changes

137 on file
DateFirm ActionFromTo
Aug 6, 26 TD Cowen MAINTAINED Buy Buy
Aug 6, 26 RBC Capital MAINTAINED Outperform Outperform
Aug 6, 26 Truist Securities MAINTAINED Buy Buy
Aug 6, 26 Guggenheim MAINTAINED Buy Buy
Aug 6, 26 Barclays MAINTAINED Overweight Overweight
Aug 6, 26 Citizens MAINTAINED Market Outperform Market Outperform
Jul 23, 26 JP Morgan MAINTAINED Overweight Overweight
Jul 14, 26 Barclays MAINTAINED Overweight Overweight
Jul 13, 26 Jefferies UPGRADE Hold Buy
Jul 7, 26 RBC Capital MAINTAINED Outperform Outperform
Jul 7, 26 Truist Securities MAINTAINED Buy Buy
Jul 1, 26 Citizens MAINTAINED Market Outperform Market Outperform

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.